Afatinib

COMPOSITION:

Each film-coated tablet contains Afatinib dimaleate 59.12 mg equivalent to Afatinib……………… 40mg.

INDICATION:

LuciAfa is a kinase inhibitor indicated for:

• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations.

• Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.

DOSAGE AND USE:

• Recommended dose: 40 mg orally, once daily .

• Renal impairment: 30 mg orally, once daily in patients with severe renal impairment .

• Instruct patients to take LuciAfa at least 1 hour before or 2 hours after a meal .

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciAfa during Pregnancy and Lactation.